{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:58Z","timestamp":1784347438109,"version":"3.55.0"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7556-26","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:10:43Z","timestamp":1784326243000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient"],"prefix":"10.2169","author":[{"given":"Yuya","family":"Sasaki","sequence":"first","affiliation":[{"name":"Department of Hematology, Institute of Science Tokyo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Science Tokyo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisako","family":"Nakamaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Science Tokyo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Science Tokyo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Science Tokyo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Science Tokyo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Science Tokyo Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dogliotti I, Peri V, Clerico M, et al. Real life clinical outcomes of relapsed\/refractory diffuse large B cell lymphoma in the rituximab era: the STRIDER study. Cancer Med 13: e7448, 2024.","DOI":"10.1002\/cam4.7448"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Engelberts PJ, Hiemstra IH, Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52: 102625, 2020.","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II Trial. J Clin Oncol 41: 2238-2247, 2023.","DOI":"10.1200\/JCO.22.01725"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Izutsu K, Kumode T, Yuda J, et al. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci 114: 4643-4653, 2023.","DOI":"10.1111\/cas.15996"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse largeB-cell lymphoma:results from the internationalSCHOLAR-1study. Blood 130: 1800-1808, 2017.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yasuda H, Komatsu N, Ando J, Ando M. Hodgkin lymphoma on hemodialysis: a review of treatment and recommendations. Clin Lymphoma Myeloma Leuk 22: 805-811, 2022.","DOI":"10.1016\/j.clml.2022.07.008"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review. Cancer Sci 112: 2607-2624, 2021.","DOI":"10.1111\/cas.14933"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J Hematol 71: 219-222, 2002.","DOI":"10.1002\/ajh.10213"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Khouderchah CJ, Ochs M, Pianko M, et al. Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis. J Oncol Pharm Pract 30: 1089-1095, 2024.","DOI":"10.1177\/10781552241242022"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wyngaert ZV, Martinez IR, Chedeville C, et al. Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis. Clin Hematol Int 6: 46-50, 2024.","DOI":"10.46989\/001c.116800"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hoffmann M, Jeker B, Huynh-Do U, et al. Elranatamab for relapsed\/refractory multiple myeloma with severe renal impairment requiring hemodialysis. Hematol Oncol 43: e70120, 2025.","DOI":"10.1002\/hon.70120"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lebreton P, Lachenal F, Bouillie S, et al. Teclistamab for relapsed refractory multiple myeloma patients on dialysis. Br J Haematol 205: 2077-2079, 2024.","DOI":"10.1111\/bjh.19772"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Thieblemont C, Karimi YH, Ghesquieres H, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38: 2653-2662, 2024.","DOI":"10.1038\/s41375-024-02410-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 387: 2220-2231, 2022.","DOI":"10.1056\/NEJMoa2206913"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7556-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:25:47Z","timestamp":1784345147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7556-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":14,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7556-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7556-26"}}